GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies
for Gynaecological Cancers
Pranav Birje | Senior Correspondent • Jemperli (dostarlimab) is India’s first and only approved PD-1 immunotherapy for second-line…
Read More